Do analysts recommend XRTX or BIVI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, XRTX or BIVI?

XORTX Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XORTX Therapeutics N/A N/A -$2.66M -$2.63 N/A BioVie N/A N/A -$17.54M -$2.45 N/A

Is XRTX or BIVI more profitable?

BioVie's return on equity of -101.15% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -150.01% -106.53% BioVie N/A -101.15% -90.18%

Does the media favor XRTX or BIVI?

In the previous week, XORTX Therapeutics' average media sentiment score of 1.89 equaled BioVie'saverage media sentiment score. Company Overall Sentiment XORTX Therapeutics Very Positive BioVie Very Positive

Do analysts prefer XRTX or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer XRTX or KPRX?

Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 280.23%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XRTX or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -59.30% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -150.01% -106.53% Kiora Pharmaceuticals N/A -59.30% -41.23%

Do analysts recommend PHIO or XRTX?

Phio Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,259.22%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, PHIO or XRTX?

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A XORTX Therapeutics N/A N/A -$2.66M -$2.63 N/A

Is PHIO or XRTX more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -77.34% -70.87% XORTX Therapeutics N/A -150.01% -106.53%

Do analysts prefer XRTX or TRAW?

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 49.03%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60

Is XRTX or TRAW more profitable?

XORTX Therapeutics' return on equity of -150.01% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -150.01% -106.53% Traws Pharma N/A -913.18% -133.88%

XORTX Therapeutics (XRTX) Competitors

$2.01 -0.10 (-4.74%)

Closing price 04:00 PM Eastern

Extended Trading

$2.01 0.00 (0.00%)

As of 04:41 PM Eastern

Compare

XRTX vs. BIVI, BLRX, KPRX, PHIO, and TRAW

Should you buy XORTX Therapeutics stock or one of its competitors? MarketBeat compares XORTX Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XORTX Therapeutics include BioVie (BIVI), BioLineRx (BLRX), Kiora Pharmaceuticals (KPRX), Phio Pharmaceuticals (PHIO), and Traws Pharma (TRAW). These companies are all part of the "med - drugs" industry.

How does XORTX Therapeutics compare to BioVie?

XORTX Therapeutics (NASDAQ:XRTX) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

BioVie's return on equity of -101.15% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
BioVie	N/A	-101.15%	-90.18%

XORTX Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, BioVie has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

In the previous week, XORTX Therapeutics' average media sentiment score of 1.89 equaled BioVie'saverage media sentiment score.

Company	Overall Sentiment
XORTX Therapeutics	Very Positive
BioVie	Very Positive

XORTX Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 0.9% of BioVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioVie beats XORTX Therapeutics on 5 of the 8 factors compared between the two stocks.

How does XORTX Therapeutics compare to BioLineRx?

XORTX Therapeutics (NASDAQ:XRTX) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

XORTX Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

XORTX Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
BioLineRx	-563.70%	-37.73%	-19.42%

In the previous week, BioLineRx had 1 more articles in the media than XORTX Therapeutics. MarketBeat recorded 1 mentions for BioLineRx and 0 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 1.89 beat BioLineRx's score of 1.27 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
XORTX Therapeutics	Very Positive
BioLineRx	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioLineRx has higher revenue and earnings than XORTX Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
BioLineRx	$1.18M	10.74	-$1.17M	-$1.92	N/A

Summary

BioLineRx beats XORTX Therapeutics on 8 of the 12 factors compared between the two stocks.

How does XORTX Therapeutics compare to Kiora Pharmaceuticals?

XORTX Therapeutics (NASDAQ:XRTX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

XORTX Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market.

XORTX Therapeutics has higher earnings, but lower revenue than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.71	N/A

Kiora Pharmaceuticals' return on equity of -59.30% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 280.23%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, XORTX Therapeutics' average media sentiment score of 1.89 beat Kiora Pharmaceuticals' score of 1.44 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
XORTX Therapeutics	Very Positive
Kiora Pharmaceuticals	Positive

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Kiora Pharmaceuticals beats XORTX Therapeutics on 7 of the 13 factors compared between the two stocks.

How does XORTX Therapeutics compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Phio Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than XORTX Therapeutics. MarketBeat recorded 1 mentions for Phio Pharmaceuticals and 0 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 1.89 beat Phio Pharmaceuticals' score of 0.69 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Phio Pharmaceuticals	Positive
XORTX Therapeutics	Very Positive

Phio Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,259.22%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A

Phio Pharmaceuticals' return on equity of -77.34% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
XORTX Therapeutics	N/A	-150.01%	-106.53%

Summary

Phio Pharmaceuticals beats XORTX Therapeutics on 10 of the 13 factors compared between the two stocks.

How does XORTX Therapeutics compare to Traws Pharma?

XORTX Therapeutics (NASDAQ:XRTX) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

XORTX Therapeutics' return on equity of -150.01% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
Traws Pharma	N/A	-913.18%	-133.88%

Traws Pharma has higher revenue and earnings than XORTX Therapeutics. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
Traws Pharma	$2.79M	3.64	$9.17M	-$1.69	N/A

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by insiders. Comparatively, 7.6% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 49.03%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

In the previous week, XORTX Therapeutics' average media sentiment score of 1.89 beat Traws Pharma's score of 0.97 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
XORTX Therapeutics	Very Positive
Traws Pharma	Positive

XORTX Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

Summary

Traws Pharma beats XORTX Therapeutics on 9 of the 12 factors compared between the two stocks.

Get XORTX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XRTX vs. The Competition

Export

Metric	XORTX Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.48M	$3.04B	$6.84B	$12.25B
Dividend Yield	N/A	2.09%	2.68%	8.86%
P/E Ratio	-0.76	19.91	27.24	23.92
Price / Sales	N/A	802.20	582.84	112.91
Price / Cash	N/A	56.84	49.25	59.89
Price / Book	1.34	4.26	10.69	6.18
Net Income	-$2.66M	$65.46M	$3.59B	$331.73M
7 Day Performance	-4.29%	-3.18%	-2.17%	-2.30%
1 Month Performance	-6.51%	0.73%	2.08%	-1.62%
1 Year Performance	-53.79%	17.34%	24.68%	16.80%

XORTX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XRTX XORTX Therapeutics	0.4622 of 5 stars	$2.01 -4.7%	N/A	-50.4%	$3.48M	N/A	N/A	N/A	Positive News
BIVI BioVie	0.4884 of 5 stars	$1.72 -2.8%	N/A	-76.5%	$13.35M	N/A	N/A	10	Gap Up
BLRX BioLineRx	0.8004 of 5 stars	$2.98 +2.4%	N/A	-35.2%	$12.71M	$1.18M	N/A	40	News Coverage Positive News Gap Up
KPRX Kiora Pharmaceuticals	3.3926 of 5 stars	$2.55 +2.8%	$10.00 +292.2%	-19.0%	$10.99M	$16.02M	N/A	10	Positive News Analyst Upgrade High Trading Volume
PHIO Phio Pharmaceuticals	4.0703 of 5 stars	$1.00 +12.3%	$14.00 +1,300.1%	-58.0%	$10.34M	N/A	N/A	10	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XRTX) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XORTX Therapeutics (XRTX) Competitors

XRTX vs. BIVI, BLRX, KPRX, PHIO, and TRAW

How does XORTX Therapeutics compare to BioVie?

Summary

How does XORTX Therapeutics compare to BioLineRx?

Summary

How does XORTX Therapeutics compare to Kiora Pharmaceuticals?

Summary

How does XORTX Therapeutics compare to Phio Pharmaceuticals?

Summary

How does XORTX Therapeutics compare to Traws Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX vs. The Competition

XORTX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XORTX Therapeutics (XRTX) Competitors

XRTX vs. BIVI, BLRX, KPRX, PHIO, and TRAW

How does XORTX Therapeutics compare to BioVie?

Is XRTX or BIVI more profitable?

Which has more volatility & risk, XRTX or BIVI?

Does the media favor XRTX or BIVI?

Which has stronger valuation and earnings, XRTX or BIVI?

Do institutionals and insiders have more ownership in XRTX or BIVI?

Do analysts recommend XRTX or BIVI?

Summary

How does XORTX Therapeutics compare to BioLineRx?

Do institutionals and insiders have more ownership in XRTX or BLRX?

Which has more volatility & risk, XRTX or BLRX?

Is XRTX or BLRX more profitable?

Does the media favor XRTX or BLRX?

Do analysts prefer XRTX or BLRX?

Which has stronger earnings & valuation, XRTX or BLRX?

Summary

How does XORTX Therapeutics compare to Kiora Pharmaceuticals?

Which has more volatility and risk, XRTX or KPRX?

Which has higher valuation and earnings, XRTX or KPRX?

Is XRTX or KPRX more profitable?

Do analysts prefer XRTX or KPRX?

Does the media favor XRTX or KPRX?

Do insiders & institutionals have more ownership in XRTX or KPRX?

Summary

How does XORTX Therapeutics compare to Phio Pharmaceuticals?

Do insiders & institutionals believe in PHIO or XRTX?

Which has more risk & volatility, PHIO or XRTX?

Does the media favor PHIO or XRTX?

Do analysts recommend PHIO or XRTX?

Which has better earnings and valuation, PHIO or XRTX?

Is PHIO or XRTX more profitable?

Summary

How does XORTX Therapeutics compare to Traws Pharma?

Is XRTX or TRAW more profitable?

Which has higher valuation & earnings, XRTX or TRAW?

Do institutionals & insiders hold more shares of XRTX or TRAW?

Do analysts prefer XRTX or TRAW?

Does the media refer more to XRTX or TRAW?

Which has more risk and volatility, XRTX or TRAW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX vs. The Competition

XORTX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools